Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Humana Doubles Down on Hospice Services
Humana Inc. (NYSE: HUM) is moving more deeply into hospice care with its recent announcement that it will acquire Philadelphia-based Enclara Healthcare from Consonance Capital Partners and Enclara management. Enclara is one of the largest hospice and pharmacy benefit management (PBM) providers in the country, serving 450 hospice providers and 97,000 hospice patients daily. This deal includes mail-order pharmacy Enclara Pharmacia, specialty PBM GuidantRx and pharmacy Avanti Health Care Services. Enclara’s palliative care provider, Turn-Key Health, is not included. Consonance first invested in Enclara in 2014 and added ExcelleRx, PGM Holdings and Avanti Health Care Services in the... Read More »
Diplomat Pharmacy, under Pressure, Merges with OptumRx
In early November, Diplomat Pharmacy, Inc. (NYSE: DPLO) revealed some troubling news. The company reported a net loss of $177.3 million in its third-quarter earnings report, its third in a row, and issued a “going concern” warning. Shares dropped 50% (from $6.20 to $3.10) that morning. Brian Griffin, chairman and CEO of Diplomat, cited industry headwinds pressuring its prescription benefits management (PBM) business, and its failure to renew network participation in their specialty pharmacy network. Diplomat’s PBM segment generated $82 million in Q3:19, compared to $170 million in the same quarter last year. Diplomat Pharmacy’s efforts to expand in the PBM sector... Read More »eHealth Deals Soar in 2019
It almost goes without saying that technology has permeated every aspect of healthcare, but dealmaking in 2019 underscores that point even further. Based on preliminary numbers, eHealth deals hit a record 212 this year, a slight uptick from 2018’s deal count of 204, according to our Deal Search Online database. Source: HealthcareMandA.com, December 2019 The graph above breaks out the number of deals by target type. Companies focused on providing management software solutions to support back-office operations led the sector this year, with 46 deals. These are usually small firms offering software-as-a-service (SaaS) platforms that could be implemented to aid any type of healthcare... Read More »
Tenet Sells Two Hospitals for $350 Million
In its first sale of 2019, Tenet Healthcare Corporation (NYSE: THC) is divesting two of its Memphis-area hospitals to Methodist Le Bonheur Healthcare, which operates six acute-care and one children’s hospital in and around Memphis. The not-for-profit health system will pay $350 million in cash for Saint Francis Hospital-Memphis (353 beds) and Saint Francis Hospital-Bartlett (156 beds), the physician practices associated with both hospitals, and six MedPost urgent care centers. The transaction is expected to be completed in 2020. The agreement provides that Tenet’s Conifer Health Solutions subsidiary will continue to provide revenue cycle management services to the hospitals.... Read More »
Health Care M&A Deals, Week Ending December 13, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Behavioral Health Care Acquirer Target Price Acorn Health Behavior Therapy Specialists N/A Biotechnology Acquirer Target Price Sanofi Synthorx, Inc. $2,500,000,000 Merck & Co., Inc. ArQule, Inc. $2,700,000,000 eHealth Acquirer Target Price InSight Telepsychiatry... Read More »
Cancer Treatments Are Driving Biopharmaceutical M&A
It’s been a busy year for mergers and acquisitions in the Biotechnology and Pharmaceutical industries. Combined spending on M&A is close to $268 billion mid-way through December, with 229 transactions reported. Although the number of deals is 34% lower than 2018’s combined total of 345, spending skyrocketed 62%, from just $165 billion in all of 2018. Two recent deals from major drug manufacturers highlight what’s behind the trend. On December 9, Sanofi announced its $2.5 billion acquisition of Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company focused on treating cancer and autoimmune disorders. The price consists of $68 per share, a 172% premium to... Read More »
AstraZeneca Divests More of Seroquel
Piece by piece, AstraZeneca (NYSE: AZN) continues to divest the rights of Seroquel and Seroquel XR (Seroquel), a prescription drug for schizophrenia and bipolar, in various major markets. It used to be a big seller for the pharmaceutical giant over the years but has since declined considerably after the FDA approved a generic version of the drug in May 2017. In 2017, Seroquel recorded sales of $332 million, representing a year-over-year decline of 55%. As a result, AstraZeneca has found buyers to take the drug off their portfolio. However, it also gives AstraZeneca the opportunity to focus on its three main therapy areas of oncology, cardiovascular, renal & metabolism, and respiratory.... Read More »
Baxter International Adds Seprafilm
Baxter International Inc. (NYSE: BAX) is having a busy 2019. After acquiring Cheetah Medical in September for $190 million in cash, it announced last week it was taking Seprafilm off of Sanofi’s (NYSE: SNY) hands. Sanofi will get $350 million for the portfolio, which includes Seprafilm Adhesion Barrier and related assets. The product is indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce adhesions between the abdominal wall and the underlying viscera. Seprafilm had global sales of $100 million in the past 12 months, including in markets such as the United States, Japan, China, South Korea and France. This acquisition builds... Read More »
Healthcare Investors’ Attention Was on Turkeys in November
Thanksgiving came very late in November this year, landing on the 28th. That cuts the December shopping season down to four weeks, but it extended the time frame for getting deals done. With a preliminary total of 126 transactions for the month, it doesn’t feel as if anyone was in a rush to close their transactions. November’s deal volume was 14% lower than the previous month, which now totals 146 transactions. Compared with the roaring 165 deals announced in November 2018, the monthly total is down by 24%. Yes, more deals will pop up on the radar, as they were last month. We started with a total of 136 then and discovered 10 more. That’s how it goes, but 10 more deals here won’t move the... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
